ModifiedUnitedHealthcarePolicy CS079TN.U

Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Tennessee Only)

This Tennessee Medicaid/CoverKids medical policy governs coverage and medical necessity for minimally invasive procedures (endoscopic, endoluminal, laparoscopic) for upper GI conditions including gastroparesis, achalasia, GERD, and related interventions; it applies to Medicaid and CoverKids members in Tennessee.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Tennessee Only)

Policy CodePolicy CS079TN.U

Change TypeMaterial coverage additions and clarifications

Effective Date04/01/2026

Next Review Date

Key ActionWhen requesting prior authorization for GES or pyloroplasty, submit documentation of failed prior therapies and relevant objective testing to demonstrate medical necessity.

SourceLink

POLICY UPDATE CHANGES

Title changed from 'Minimally Invasive Procedures for Gastric and Esophageal Diseases (for Tennessee Only)' to 'Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Tennessee Only)'.

Added related policy reference link to the Drug Policy titled 'Botulinum Toxins A and B - Coverage Rationale'.

Specified GES (gastric electrical stimulation) is proven and medically necessary for refractory gastroparesis and chronic intractable nausea and vomiting secondary to diabetic or idiopathic gastroparesis.

Specified surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for refractory gastroparesis that has failed other therapies.

Removed language indicating functional lumen imaging probe technology is unproven and not medically necessary for diagnosing achalasia.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

Added standard policy language about benefit coverage being determined by federal, state, or contractual requirements and medical record documentation requirements for medical necessity reviews.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

jurisdiction / applicability

CS079TN.Upolicy identifier

04/01/2026effective date

75%GES symptom improvement

61–86%pyloroplasty success

Coverage Criteria and Evidence Summaries

GES — covered indications

Covered when ALL of the following are met:

Gastric electrical stimulation (GES): GES is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to diabetic or idiopathic gastroparesis.

Refer to the FDA section for labeling/HDE information.

Pyloroplasty — covered indications

Covered when ALL of the following are met:

Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to diabetic or idiopathic gastroparesis.

POEM — covered and not covered indications

POEM: Per oral endoscopic myotomy (POEM) is proven and medically necessary for treating individuals with Achalasia or Diffuse Esophageal Spasm.

Requires advanced endoscopic skillset; see procedure description.

POEM — other indications: Per oral endoscopic myotomy (POEM) is unproven and not medically necessary for all other indications (e.g., Zenker's diverticula) due to insufficient evidence of efficacy.

GERD — not medically necessary interventions

GERD endoscopic and endoluminal therapies: Endoscopic therapies, injection/implantation techniques, the LINX Reflux Management System, and endoluminal therapy with GERDx are unproven and not medically necessary for treating GERD due to insufficient evidence of efficacy or lack of FDA approval.

Specific devices named in policy include GERDx, LINX, Plexiglas/PMMA, Durasphere, Stretta, MUSE, EsophyX/TIF.

Evidence summary — GES

Evidence summary for GES: Multiple single-center series, comparative observational studies, systematic reviews, and HTAs report mixed evidence: uncontrolled series often report symptom improvement, reduced medication use and fewer hospitalizations, but randomized and controlled data are inconsistent; device removal, generator exchange, lead complications and mechanical failures are reported.

See Cassidy 2024; Samaan 2022; Heckert 2016; Rajamanuri 2021; Hayes HTA; Levinthal & Bielefeldt; ACG guidance.

Coverage-relevant evidence summaries

Evidence-based statements and guideline positions relevant to coverage decisions for GES, pyloroplasty, and POEM:

GES for refractory gastroparesis: Professional guidance indicates GES may be considered as an option for medically refractory diabetic or idiopathic gastroparesis or refractory nausea/vomiting after failure of standard therapy (guidance notes low-quality evidence).

AGA and ACG guidance referenced; consider opioid status and prior therapies.

Surgical pyloroplasty (including laparoscopic pyloroplasty) has observational evidence of symptomatic and gastric emptying improvement and may be considered a surgical option for refractory gastroparesis.

SAGES and systematic reviews report improvement; combinations with GES show variable added benefit.

POEM for achalasia: Randomized and observational evidence supports POEM as effective for achalasia (noninferior to laparoscopic Heller myotomy and preferred for type III achalasia), though some studies report higher reflux rates post-POEM.

Werner RCT and AGA guidance referenced.

Evidence summaries for Z-POEM, G-POEM, and Stretta

Summary of available evidence and implications for coverage decisions

Z-POEM evidence summary: Comparative observational studies and meta-analyses suggest Z-POEM can achieve high clinical success in expert centers versus flexible endoscopic septotomy, but available studies are retrospective, single-center, and heterogeneous; prospective long-term comparative data are needed.

Singh 2025; Al Ghamdi 2022; Zhang 2022 cited.

G-POEM evidence summary: Systematic reviews, meta-analyses, observational studies and a small RCT suggest G-POEM can improve symptoms and gastric emptying in many patients with refractory gastroparesis (pooled ~70% one-year clinical success), but evidence quality is low and larger multicenter RCTs with longer follow-up are needed.

Mandarino 2024; Martinek 2022; ECRI assessments referenced.

Stretta evidence summary: Evidence for Stretta is mixed and generally low quality; some systematic reviews and nonrandomized studies report symptom improvement and reduced PPI use, but a double-blind sham-controlled RCT did not show superiority over sham, leaving comparative effectiveness versus fundoplication uncertain.

COVERAGE CRITERIA — general coverage considerations contingent on documented candidacy

Coverage considerations are driven by limited, low-quality evidence; when considered, coverage is contingent on documented candidacy and expected benefit:

Suggested clinical prerequisites: Patient has chronic or refractory GERD symptoms with objective evidence (for GERD procedures) or refractory gastroparesis symptoms despite standard therapies (for gastroparesis procedures); baseline objective testing and endoscopic evaluation are documented and informed consent includes discussion of limited long-term durability and comparative uncertainty.

Trials and device labeling commonly required pH testing, GERD-HRQL, hiatal hernia assessment, and documentation of failed optimized therapy.

Procedures with some supportive evidence: Selected endoscopic fundoplication (EFTP/EsophyX/MUSE), Stretta, TIF, and MSA have trials and systematic reviews showing symptomatic improvement in selected patients, but evidence quality and durability vary and may limit routine coverage absent documented candidacy.

See EFTP RCTs and TIF observational/controlled studies; policy emphasizes limited quality and need for longer-term data.

Coverage-relevant evidence summaries

Evidence summaries and conclusions regarding coverage-relevant outcomes

TIF evidence summary: TIF (EsophyX) has observational studies and some RCT data showing short- to mid-term symptomatic improvement and substantial rates of PPI discontinuation, but limitations include small studies, loss to follow-up, and limited long-term comparative data versus Nissen fundoplication.

Testoni, Trad, McCarty, Richter referenced.

MSA (LINX) evidence summary: MSA shows high rates of symptom control and PPI discontinuation in short- to mid-term studies and RCT evidence of superiority to double-dose PPI for regurgitation, but concerns remain about postoperative dysphagia, device removal/erosion, and limited long-term comparative data.

Bell RCT and Hayes HTA referenced; device removal and dysphagia rates noted.

Injectables/bulking agents: Injectable bulking agents (Plexiglas, Durasphere) have limited evidence from small case series, insufficient to establish long-term safety and effectiveness.

Policy cites lack of quality evidence and need for randomized studies.

Contextual coverage considerations for procedural GERD and gastroparesis therapies — covered when ALL conditions are met

Covered when ALL of the following contextual conditions are met (per cited trials/guidelines and device labels):

Objective GERD evidence: Patient has objective evidence of GERD (e.g., pathologic esophageal acid exposure or abnormal pH monitoring) consistent with guideline recommendations for antireflux interventions.as per guideline

ACG recommends antireflux surgery as an option for patients with objective GERD.

Refractory symptoms: Persistent troublesome regurgitation or heartburn despite optimized medical therapy (e.g., PPI) or patient declines ongoing pharmacologic therapy.failed medical management or patient preference

Bell et al. RCT and ACG guideline support MSA consideration for regurgitation refractory to medical therapy.

Procedure-specific candidacy:

Procedures for refractory gastroparesis — revision-added determinations

Selected coverage posture and procedure-specific determinations added or clarified in revision history:

Gastric electrical stimulation (GES): GES therapy is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to diabetic or idiopathic gastroparesis.failed other therapies

Relocated language from another Tennessee-only policy in the revision history.

Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory gastroparesis that has failed other therapies.failed other therapies

Added/clarified in revision history.

The policy explicitly identifies a range of named endoscopic and endoluminal therapies and devices that are evaluated for gastroesophageal reflux disease (GERD). Examples described in the document include transoral incisionless fundoplication with the EsophyX system (TIF), endoscopic full-thickness plication devices such as GERDx™ and the MUSE™ stapling system, radiofrequency ablation with the Stretta system, endoscopic plication/suturing systems, injectable bulking agents (e.g., Plexiglas®/PMMA and Durasphere®), and the laparoscopically implanted LINX™ Reflux Management System.

Within the excerpt provided, the policy does not list any blanket procedural exclusions beyond the device- and indication-specific not medically necessary statements; revision notes indicate removal of certain prior language but do not introduce new universal procedure exclusions in this section.

Endoscopic therapies for GERD (including endoluminal approaches, injection/implantation techniques, and several named devices) are described in the policy as unproven and not medically necessary for treating GERD when evidence of efficacy or FDA approval is insufficient; the document highlights small, heterogeneous studies, limited follow-up, and methodological limitations as the basis for this determination.

Endoscopic plication/suturing techniques (for example, endoluminal plication systems and suturing devices) and polymer injection approaches are characterized as having insufficient high-quality evidence to support durable long-term control of GERD. The policy cites limitations including small sample sizes, short follow-up, inconsistent outcome measures, and lack of randomized controlled data when concluding these approaches are unproven.

Injectable bulking agents such as Plexiglas® (PMMA) and Durasphere® are noted as having limited supporting evidence—primarily small case series—and are described as lacking sufficient data to be considered proven effective and safe for GERD; the policy identifies the need for additional randomized studies and points out that some device uses would be off-label.

The policy provides informational cautions for the Enterra™ gastric electrical stimulation system as reported in FDA labeling: the device carries a Humanitarian Device Exemption (HDE) indication for chronic, intractable nausea and vomiting due to diabetic or idiopathic gastroparesis and should not be used in patients with gastric obstruction or pseudo-obstruction, prior gastric resection or fundoplication, eating disorders, history of seizures, primary swallowing disorders, chemical dependency, or psychogenic vomiting.

The policy revision history documents removal of prior explicit language asserting that functional lumen imaging probe (FLIP) technology was unproven and not medically necessary for diagnosing achalasia; that specific statement was deleted during the update and is no longer present in the current excerpt.

Per the policy, POEM (per oral endoscopic myotomy) is considered proven and medically necessary only for treating Achalasia and Diffuse Esophageal Spasm. The document explicitly states POEM is unproven and not medically necessary for other indications (for example, Zenker's diverticulum), reflecting limited evidence outside the stated esophageal motility disorders.

The policy emphasizes that many endoscopic and endoluminal procedures lack robust comparative evidence or long-term outcomes. Cited limitations include small, single-center studies, heterogeneous patient selection, short follow-up, and absence of randomized or well-controlled comparative trials—factors that reduce confidence in durability and comparative effectiveness versus surgical alternatives.

The policy references a randomized, double-blind, sham-controlled trial (Zerbib et al.) of the Stretta radiofrequency procedure in 62 patients that did not show superiority of the active procedure over sham for key clinical outcomes; this trial is cited as evidence supporting uncertainty about Stretta's effectiveness compared with control.

EndoCinch and similar endoscopic suturing approaches are reported to lack long-term benefit in randomized and long-term follow-up studies: while some short-term symptom improvement occurred, the majority of patients still required proton pump inhibitor therapy over extended follow-up, leading the policy to consider such procedures not beneficial for long-term management.

Systematic reviews and meta-analyses of transoral incisionless fundoplication (TIF/EsophyX) are noted to have important limitations: studies are small or observational, follow-up durations vary and often are short, and indirect comparisons to laparoscopic fundoplication show inconsistent physiologic benefit. These limitations reduce confidence in TIF as a long-term alternative to established surgical approaches.

Multiple reviews and health-technology assessments cited in the policy conclude that long-term efficacy and durability remain uncertain for several endoluminal therapies (for example, radiofrequency ablation and EsophyX TIF); uncertainty about objective reflux reduction and durability of symptom control underlies the policy's cautious stance and potential noncoverage of these interventions pending stronger long-term data.

As noted in the policy revision history, earlier explicit language stating that functional lumen imaging probe (FLIP) technology was unproven and not medically necessary for diagnosing achalasia was removed during the update; the current document does not retain that prior negative statement about FLIP.

Applicable Codes and Regulatory References

Applicable CPT codes (group 1)CPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43497	Lower esophageal myotomy, transoral (i.e., peroral endoscopic myotomy [POEM]).
43499	Unlisted procedure, esophagus.
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.

Applicable CPT codes (group 2)CPT

43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open.
43999	Unlisted procedure, stomach.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.

FDA 510(k) referencesmixed

K233240

FDA 510(k) number referenced for GERDx-System (Product Code ODE) submission May 24, 2024

Hiatal hernia size for EsophyX indication — clinical limit

Hiatal hernia size for EsophyX indication< 2 cm

Device indication sourceEsophyX/EsophyX2 FDA 510(k) clearance summary includes reduction of hiatal hernia < 2 cm

Documentation expectationHiatal hernia size should be documented by endoscopy or imaging prior to EsophyX/TIF

Prior Authorization, Documentation, and Operational Guidance

Prior Authorization

Prior authorization may be required for listed procedure codes

Procedures and device implantations listed in the policy (see CPT/HCPCS codes) are referenced for coverage determination and may require prior authorization per state Medicaid/CoverKids processes.

See policy-provided CPT codes (e.g., 43497, 43647, 43648, 43284, 64590) for procedures/devices that may be subject to authorization.

Prior Authorization

Expect prior authorization and detailed justification for specialized procedures

Advanced or specialized interventions (GES, POEM, pyloroplasty, Z-POEM) are supported by limited-to-moderate evidence; providers should submit severity scores, prior therapy failures, and objective testing with authorization requests to justify medical necessity.

Include symptomatic severity scores (e.g., PAGI-SYM, Eckardt) and documentation of failed standard therapies.
Provide relevant objective testing results (e.g., gastric emptying studies for GES; manometry for POEM).

Clinical Background and Definitions

Gastroparesis is a disorder of delayed gastric emptying presenting with symptoms such as nausea, vomiting, early satiety, and abdominal pain. The policy notes that gastroparesis can lead to significant morbidity including hospitalizations and metabolic complications, and that interventions discussed (for example, GES, pyloroplasty, and endoscopic pyloric therapies) are considered in patients with refractory symptoms after failure of conservative therapies.

Definition — Achalasia

TermAchalasia

DefinitionA primary esophageal motor disorder characterized by degeneration of the myenteric plexus resulting in impaired relaxation of the esophagogastric junction and loss of organized peristalsis.

SourceASGE (policy definitions)

Definition — Diffuse Esophageal Spasm

TermDiffuse Esophageal Spasm

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Tennessee Only)

Policy CodePolicy CS079TN.U

Change TypeMaterial coverage additions and clarifications

Effective Date04/01/2026

Next Review Date

Key ActionWhen requesting prior authorization for GES or pyloroplasty, submit documentation of failed prior therapies and relevant objective testing to demonstrate medical necessity.

SourceLink

On This Page

Z-POEM for Zenker's diverticulum: Z-POEM may be a feasible alternative to flexible endoscopic septotomy in expert centers with comparable short-term outcomes, but long-term comparative data are limited and heterogeneous.

Meta-analyses and retrospective studies limited by design and follow-up.

ECRI and Hayes assessments cited; Zerbib RCT noted.

Anatomic and device-specific criteria are met (for example, hiatal hernia ≤2 cm for some endoluminal devices) and no device-specific contraindications are present.

device labeling and procedural indications

EsophyX label and Enterra contraindications referenced in policy.

Provider expertise and setting: Procedure performed by appropriately trained and experienced clinicians in centers with requisite expertise.per society guidance

SAGES and AGA recommend experienced operators and high-volume centers for POEM, LINX, and TIF.

Prior Authorization

Prior authorization likely required for unproven/novel endoscopic procedures

Many novel or unproven endoscopic procedures for GERD and newer myotomy techniques have limited, low-quality, or short-term evidence; payers may require prior authorization and additional documentation or may deem them investigational.

Authorization requests should include evidence of refractory symptoms and prior treatments.
Anticipate closer review or potential noncoverage when long-term durability or comparative evidence is lacking.

Prior Authorization

PA for endoscopic fundoplication/TIF requires failed/undesirable long-term PPI and objective testing

Authorization for endoscopic fundoplication/TIF should include documentation of failed or undesirable long-term PPI therapy and objective diagnostic testing (e.g., abnormal esophageal acid exposure, hiatal hernia assessment) to support candidacy.

Provide baseline GERD-HRQL and pH monitoring/DeMeester score when available.
Document prior PPI duration, dose, and response (or patient refusal of long-term PPI).

Documentation Required

Document eligibility criteria used in MSA/TIF trials (pH, hernia size, BMI, motility)

Trials and device-label eligibility used for MSA/TIF authorization include abnormal pH testing, small hiatal hernia (e.g., ≤2–3 cm depending on device), BMI limits, and absence of advanced esophagitis or Barrett's; documentation of these criteria may be required.

Document hiatal hernia size (EsophyX indication notes <2 cm; trial inclusion commonly used <3 cm).
Include preoperative endoscopy, pH testing, and manometry as applicable.

Note

Confirm device approvals/clearances and include in PA submissions

Device regulatory status and labeling should be checked when requesting authorization: Enterra has an FDA HDE for refractory nausea/vomiting in gastroparesis; Stretta, EsophyX/EsophyX2, MUSE, and LINX have FDA clearances/approvals with specific indications and labeling that affect prior authorization.

Review device-specific FDA indications (e.g., Enterra HDE age/indication limits, EsophyX indications including hiatal hernia <2 cm).
Provide device manufacturer and model in authorization request when applicable.

Note

Coverage determination depends on benefit rules and documentation

Benefit coverage is determined by federal, state, or contractual requirements; medical records documentation may be required to assess whether the member meets clinical criteria but does not guarantee coverage.

Ensure records submitted clearly support that the member meets the policy clinical criteria for the requested service.

Documentation Required

Provider must supply complete medical record to support medical necessity

The patient's medical record must fully support medical necessity for the requested procedure, including relevant medical history, physical examination, and results of pertinent diagnostic tests; documentation must be legible and available upon request.

Include symptom scores, prior therapies tried, objective testing results, and informed consent discussion of risks/limitations.

Step Therapy

Step therapy: consider GES or pyloroplasty after failure of standard medical therapy

Guidance suggests GES or surgical pyloroplasty (including laparoscopic pyloroplasty) be considered only after failure of standard/conservative medical therapies for gastroparesis; provide documentation of prior medical management when seeking authorization.

Document prior dietary/medical measures, prokinetic trials, antiemetic use, and response before requesting GES or pyloroplasty.

Step Therapy

Require optimized PPI and conservative measures before endoscopic GERD interventions

Prior conservative therapy, including optimized PPI therapy, is typically required before considering endoscopic GERD interventions; randomized sham-controlled evidence (e.g., Stretta) did not show superiority over sham in some trials.

Document duration and dose of PPI therapy and whether symptoms persisted despite optimization.

Note

Consider continued medical management (PPI) given its effectiveness for many patients

Many analyses report that PPI therapy remains effective for many patients; continued medical management is reasonable and should be considered prior to procedural intervention.

Include rationale for moving to procedural therapy when PPI therapy is ineffective, not tolerated, or declined by the patient.

Step Therapy

Consider surgical options when symptoms persist after optimized PPI therapy

Surgical options (including MSA) are generally considered when patients have persistent troublesome regurgitation or objective GERD despite optimized PPI therapy; RCTs compared MSA to double-dose PPI for persistent regurgitation.

Document persistent regurgitation symptoms and objective testing supporting GERD prior to authorizing surgical interventions.

Documentation Required

Require objective GERD evidence before procedural therapy per guidelines

Guidelines and trials support considering surgery or MSA when patients have objective GERD and persistent regurgitation despite PPI therapy; authorization should reference guideline-based objective criteria.

Provide objective evidence (pH monitoring, endoscopy) demonstrating pathological reflux and prior medical therapy failure.

Step Therapy

Prior therapy requirement for GES and pyloroplasty (document prior failures)

GES (Enterra) and surgical pyloroplasty are described as indicated after failure of other therapies for refractory gastroparesis; include documentation of failed prior therapies when requesting authorization.

List prior therapy attempts (dietary measures, prokinetics, antiemetics) and documented lack of adequate response.

Documentation Required

Ensure patient medical record documents history, exam, and diagnostics to support necessity

Medical records must support medical necessity with relevant history, physical exam, and diagnostic test results (e.g., gastric emptying studies, pH testing, manometry); incomplete records may result in denial.

Include baseline and follow-up symptom scores, objective testing, and legible documentation in the chart.

Documentation Required

Provide validated symptom scores and objective testing per trial documentation

Trials often used validated symptom scores and objective measures; include these (e.g., Eckardt for achalasia, GCSI for gastroparesis, GERD-HRQL) in documentation submitted for authorization or medical necessity review.

Provide baseline and follow-up scores at prespecified intervals when available to demonstrate clinical response.

Documentation Required

Document G-POEM outcomes (GCSI, gastric emptying, AE monitoring)

For G-POEM authorization and follow-up, provide GCSI symptom scores, gastric emptying study results, and adverse event monitoring documentation to support clinical outcomes.

Include baseline GCSI, gastric emptying metrics, and details of any serious adverse events or complications.

Documentation Required

Document baseline GERD-HRQL, pH testing, prior PPI history, and hiatal hernia assessment

Authorization for GERD interventions should include baseline GERD-HRQL, pH testing or other objective esophageal acid exposure data, prior PPI history (duration/dose/response), and hiatal hernia assessment.

Attach endoscopy reports noting hiatal hernia size and esophagitis grade when available.

Documentation Required

Include preoperative diagnostic assessments (GERD-HRQL, endoscopy, barium swallow, pH monitoring)

Preoperative diagnostic documentation commonly reported in trials includes GERD-HRQL questionnaire, upper GI endoscopy, barium swallow, ambulatory pH monitoring, and esophageal manometry; include these studies when applicable for surgical/device authorization.

Provide recent endoscopy, pH monitoring, manometry, and imaging reports used to establish candidacy.

Note

Include FDA-cleared device indications (EsophyX/EsophyX2, MUSE) in requests

EsophyX/EsophyX2 and MUSE received FDA clearance for transoral tissue approximation and full-thickness plication to treat symptomatic chronic GERD in patients who respond to pharmacologic therapy; include device and indication details in requests.

Note EsophyX indication includes reduction of hiatal hernia <2 cm.

Denial Risk

Missing documentation may result in denial — include history, exam, diagnostics

Failure to provide medical records documentation that fully supports medical necessity (history, exam, diagnostic tests, legible records) may lead to denial or noncoverage.

Ensure records are complete, legible, and available upon request to avoid delays or denials.

Denial Risk

Evidence limitations for Enterra GES may lead to investigational denials

Insufficient comparative data and/or short follow-up for Enterra GES (case series without comparison groups) limit evidence strength; payers may deny GES as investigational when comparative or long-term data are lacking.

Provide long-term outcome data and rationale for device use when possible to support medical necessity.

Denial Risk

Unproven endoscopic GERD therapies are at risk for noncoverage

Endoscopic GERD therapies identified as unproven due to insufficient or low-quality evidence (e.g., some endoluminal approaches) may be subject to noncoverage or denial; include robust supportive data when requesting authorization.

Authorization requests should address durability, objective reflux measures, and long-term outcomes to mitigate denial risk.

Denial Risk

Denial risk if patient selection and pre-procedure evaluation are not documented

Procedures may be denied if patient selection and pre-procedure evaluation (including proper assessment of PPI use, objective testing, and candidacy) are not documented; many studies lacked appropriate pre-procedure evaluation.

Document eligibility assessment showing prior optimized medical therapy and objective test results used to select the patient.

Denial Risk

Limited long-term comparative data may lead to investigational determinations

Limited long-term comparative data and short follow-up across many interventions may render procedures investigational or unproven; provide evidence of expected durable benefit when requesting authorization.

Highlight long-term outcomes or registries when available to support coverage requests.

Documentation Required

Confirm Enterra contraindications are absent before authorization

Enterra device labeling includes contraindications; authorization requests should confirm the patient does not have listed contraindications (e.g., gastric obstruction, prior gastric resection, fundoplication, eating disorders, seizures, primary swallowing disorders, chemical dependency, psychogenic vomiting).

Verify and document absence of any Enterra contraindications from the FDA label in the medical record.

Denial Risk

Missing required documentation will likely result in denial

Failure to provide medical records that fully support medical necessity (relevant history, exam, diagnostic tests, legible records) may result in denial; ensure submitted records include the clinical details used to justify the requested procedure.

Include provider notes, diagnostic reports, symptom scores, prior treatment logs, and informed consent discussions.

DefinitionRare esophageal motility disorder characterized by simultaneous, uncoordinated, or rapidly propagated contractions of normal amplitude accompanied by dysphagia.

SourceNational Library of Medicine (policy definitions)

Definition — Gastroesophageal Reflux Disease (GERD)

TermGastroesophageal Reflux Disease (GERD)

DefinitionA condition where the lower esophageal sphincter relaxes too often or weakens allowing stomach acid to flow backward (reflux) into the esophagus.

SourceAmerican College of Gastroenterology (policy definitions)

Definition — Gastroparesis

TermGastroparesis

DefinitionA digestive disorder in which gastric motility is abnormal or absent (delayed gastric emptying); diagnosis requires objective evidence of delayed gastric emptying in symptomatic patients.

Policy noteDefinition updated in the policy (see revision history).

Definition — Gastric Electrical Stimulation (GES)

TermGastric Electrical Stimulation (GES)

DefinitionAn implanted Enterra® system that delivers electrical pulses to the stomach (gastric neurostimulator) for treatment of refractory gastroparesis symptoms, including chronic intractable nausea and vomiting of diabetic or idiopathic etiology (HDE-labeled indication).

Evidence noteCase series report symptom improvement but lack randomized/comparative long-term data; device has FDA HDE labeling and contraindications listed on label.

Definition — POEM

TermPOEM (Per oral endoscopic myotomy)

DefinitionAn endoscopic procedure creating a submucosal tunnel with myotomy of the esophageal sphincter to treat achalasia; supported by randomized and observational evidence demonstrating efficacy comparable to surgical myotomy in achalasia.

Practice noteRequires advanced endoscopic skillset; recommended to be performed by experienced operators in high-volume centers.

Definition — Z-POEM (Zenker's POEM)

TermZ-POEM (Zenker's POEM)

DefinitionPer-oral endoscopic myotomy technique applied to Zenker's diverticulum; early comparative observational studies suggest similar short-term symptom resolution to flexible endoscopic septotomy but long-term comparative effectiveness and safety remain uncertain.

Evidence limitationExisting studies are limited by retrospective designs, single-center data, variable definitions of success, and limited follow-up beyond one year.

Definition — Z-POEM (alternate chunk)

TermZ-POEM (alternate reference)

DefinitionZenker's peroral endoscopic myotomy described in meta-analyses as a feasible alternative to flexible endoscopic septotomy in expert hands with higher reported clinical success but limited by study quality and follow-up.

Research needFurther prospective, long-term comparative data are needed to determine optimal treatment strategy for Zenker's diverticulum.

Definition — G-POEM

TermG-POEM (Gastric peroral endoscopic myotomy)

DefinitionEndoscopic pyloric myotomy procedure for refractory gastroparesis intended to improve gastric emptying and symptoms; evidence includes observational series, meta-analyses, and a small RCT but long-term effectiveness and patient selection remain uncertain.

Evidence noteStudies are heterogeneous and often from tertiary centers; larger multicenter RCTs with longer follow-up are needed.

Definition — Stretta

TermStretta

DefinitionAn endoscopic radiofrequency energy delivery system intended to treat GERD by delivering thermal lesions at the gastroesophageal junction to reduce reflux symptoms and PPI dependence.

Evidence summaryEvidence is mixed and low quality; some systematic reviews suggest symptom improvement but a double-blind sham RCT did not show superiority over sham.

Definition — Stretta (alternate chunk)

TermStretta (alternate)

DefinitionEndoscopic radiofrequency energy delivery to the gastroesophageal junction intended to reduce reflux symptoms and dependence on PPIs; regulatory approvals exist and assessments note uncertain comparative effectiveness versus fundoplication.

Clinical cautionLarge, multicenter RCTs with long-term outcomes are needed to better define role and durability.

Definition — TIF / EsophyX

TermTIF / EsophyX

DefinitionTransoral incisionless fundoplication performed with the EsophyX/EsophyX2 system to create an endoluminal fundoplication (full-thickness plication) intended to reduce reflux and, per labeling, to reduce small hiatal hernias (<2 cm).

Evidence noteObservational studies and some RCT data show symptom improvement and PPI discontinuation in selected patients, but long-term comparative data versus surgical fundoplication are limited.

Definition — EFTP / GERDx / MUSE

TermEFTP / GERDx / MUSE (Endoscopic full-thickness plication)

DefinitionEndoscopic devices and techniques that create full-thickness plications or stapled fundoplications (e.g., GERDx, MUSE) to reduce reflux symptoms and PPI dependence; studied in randomized and observational trials with variable quality.

Clinical trial noteSome sham-controlled trials report symptom improvement and reduced PPI use, but larger trials with longer follow-up are required.

Definition — TIF (Transoral Incisionless Fundoplication)

TermTIF (Transoral Incisionless Fundoplication)

DefinitionAn endoscopic fundoplication procedure using the EsophyX device (TIF 2.0 described) intended to reconstruct the gastroesophageal valve and reduce reflux-related symptoms.

Outcomes noteLong-term series report substantial PPI discontinuation in some cohorts but studies often lack control groups and have variable follow-up.

Definition — MSA (LINX)

TermMSA (LINX)

DefinitionMagnetic sphincter augmentation (LINX) is a laparoscopically implanted ring of magnetic beads placed around the lower esophageal sphincter to augment sphincter function and reduce reflux.

Safety noteShort- to mid-term data show symptom control and PPI discontinuation but concerns include postoperative dysphagia, device removal/erosion, and limited long-term comparative data.

Definition — Injectable bulking agents (Durasphere/Plexiglas)

TermInjectable bulking agents (Durasphere/Plexiglas)

DefinitionEndoscopic injection of bulking materials into the gastroesophageal junction intended to reduce reflux symptoms; current evidence is limited to small case series and is insufficient to establish long-term effectiveness and safety.

Evidence cautionStudies are small and uncontrolled; additional randomized studies are warranted.

Definition — Enterra Therapy System

TermEnterra Therapy System

DefinitionAn FDA Humanitarian Device Exemption (HDE)-approved gastric electrical stimulation device (Enterra) indicated for treatment of chronic, intractable (drug-refractory) nausea and vomiting secondary to diabetic or idiopathic gastroparesis in adults 18–70.

Contraindications (label)Do not use in patients with gastric obstruction/pseudo-obstruction, prior gastric resection, fundoplication, eating disorders, seizure history, primary swallowing disorders, chemical dependency, or psychogenic vomiting.

Definition — EsophyX/EsophyX2 (TIF)

TermEsophyX/EsophyX2 (TIF)

DefinitionAn endoluminal device cleared (510(k)) for transoral tissue approximation and full-thickness plication to treat symptomatic chronic GERD and to reduce small hiatal hernias (<2 cm) in patients responsive to pharmacologic therapy.

Regulatory noteEsophyX2 cleared as substantially equivalent to predicate devices; indications include narrowing of the gastroesophageal junction and reduction of hiatal hernia <2 cm.

Definition — LINX Reflux Management System (MSA)

TermLINX Reflux Management System (MSA)

DefinitionA surgically implanted magnetic esophageal sphincter augmentation device (LINX) intended to augment the lower esophageal sphincter to treat GERD; associated with improved symptom control but potential for dysphagia and device removal.

Evidence noteSystematic reviews and RCTs report favorable short- to mid-term outcomes but long-term safety and comparative effectiveness data are limited.

Definition — Gastroparesis (updated definition reference)

TermGastroparesis (updated definition)

DefinitionA digestive disorder in which the motility of the stomach is abnormal or absent (delayed gastric emptying); diagnosis requires objective evidence of delayed gastric emptying in symptomatic patients — policy definition updated in the revision.

Policy noteUpdated definition reflected in policy history/revision information.